PDCD1 and cancer: Considering that most research utilizing anti-PD-1 as an anti-cancer immunotherapy use doses of 100 to 250 μg of the monoclonal antibody [44–46], we believe that the lack of a stronger synergistic effect for the ConvitVax/anti-PD-1 combined therapy was due to the low dose of anti-PD-1 (50 μg) applied in this work.